ROCKVILLE, Md.--(BUSINESS WIRE)--
, Inc. (NASDAQ:GLYC) announced today the appointment
of Patricia S. Andrews, chief executive officer and director of Boston
, to its Board of Directors.
"It's an asset to our Board and GlycoMimetics as a whole to be able to
leverage Pat's commercial experience in oncology," said Rachel
King, CEO of GlycoMimetics. "Her track record of leadership in
transitioning companies to the commercial stage will be particularly
helpful to us as we continue to advance our pipeline."
Ms. Andrews was named CEO of Boston Biomedical in April 2017. She joined
the company in 2013 and was most recently its Executive Vice President
and Chief Operating Officer, where she prepared for launching the
company's first product, and guided the company's pipeline development.
Previously, she was Executive Vice President and Chief Commercial
Officer at Incyte Corporation (NASDAQ:INCY), leading commercial
operations for that company's launch of first-in-class, first-in-disease
oncology product Jakafi®. Before that, she served in leadership
positions at Pfizer, Inc., where her final role was Vice President and
General Manager of the U.S. Oncology Business Unit, and at Marine
Midland/HSBC, where she was Vice President in corporate finance. Ms.
Andrews received her M.B.A. from the University of Michigan and her B.A.
from Brown University.
"I'm honored to serve on the Board of Directors of GlycoMimetics, which
has impressed me with its management team and promising pipeline of
treatments targeting some of today's most serious medical challenges in
oncology," said Ms. Andrews. "I believe these clinical assets have
potential in areas of high unmet need, and I look forward to helping the
company rapidly progress its drug candidates towards commercialization."
Ms. Andrews was introduced to GlycoMimetics through an initiative
sponsored by LifeSci
Advisors for the placement of women on boards of directors in the
life sciences industry. "On behalf of the GlycoMimetics management and
Board, I'd like to thank LifeSci Advisors for its Board
Placement Initiative, which assisted in helping to identify several
outstanding director candidates, including Pat," Ms. King added.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease. GlycoMimetics' most advanced drug
candidate, rivipansel, a pan-selectin antagonist, is being developed for
the treatment of vaso-occlusive crisis in sickle cell disease and is
being evaluated in a Phase 3 clinical trial being conducted by its
strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug
candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an
ongoing Phase 1/2 clinical trial as a potential treatment for AML and in
a Phase 1 clinical trial in multiple myeloma. The U.S. FDA recently
granted GMI-1271 Breakthrough Therapy designation for treatment of adult
AML patients with relapsed/refractory disease. GlycoMimetics has also
recently initiated a clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development and potential commercialization of its product pipeline.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including the outcomes of planned and ongoing clinical trials,
expectations for regulatory approvals and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the U.S. Securities and Exchange Commission on March 1,
2017, and other filings GlycoMimetics makes with the Securities and
Exchange Commission from time to time. In addition, the forward-looking
statements included in this press release represent GlycoMimetics' views
as of the date hereof. GlycoMimetics anticipates that subsequent events
and developments may cause its views to change. However,
while GlycoMimetics may elect to update these forward-looking statements
at some point in the future, GlycoMimetics specifically disclaims any
obligation to do so, except as may be required by law. These
forward-looking statements should not be relied upon as representing
GlycoMimetics' views as of any date subsequent to the date hereof.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170612005330/en/
For GlycoMimetics, Inc.
Source: GlycoMimetics, Inc.
News Provided by Acquire Media